In this webinar we will look at the decision in G 2/21, as well as how this might be applied by the EPO’s Boards of Appeal and national courts. We will then consider best practice for European patent applications in light of this decision, and in particular whether any changes in approach are needed.
Topics will include:
- The decision in G 2/21
- How G 2/21 is likely to be applied
- Plausibility considerations for patent applications – has anything changed?
This is a technical webinar aimed at:
- In-house IP practitioners working in the pharmaceutical and biotech sectors
- Attorneys involved in drafting, prosecuting and advising on patent applications for inventions dependent on a certain biological activity
- People involved in developing products for the biotech and healthcare sector in new and growing businesses or academic institutions
Timings: 16:00 BST, then on-demand
Speakers: Ravi Srinivasan and Guy Brain